Unicycive(US:UNCY) Prnewswire·2025-10-09 12:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Unicycive Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 29, 2024, to June 27, 2025 [1]. - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of its new drug application for oxylanthanum carbonate [1]. - As a result of these alleged misstatements, the defendants' public statements were deemed materially false and misleading throughout the relevant time [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of UNCY during the class period are encouraged to register for the class action, with a deadline to seek lead plaintiff status set for October 14, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements that inflated stock prices [3].